Overview

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

This will be an open-label uncontrolled trial to evaluate the safety and tolerability of aripiprazole IM depot administered every 4 weeks for up to 52 weeks to patients with bipolar I disorder. The trial will enroll subjects who completed Trial 31-08-250 and de novo subjects not participating in Trial 31-08-250.

Phase:

Phase 3

Details

Lead Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborator:

H. Lundbeck A/S

Treatments:

Aripiprazole